Drawing for REPERTOIRE

USPTO serial 88774013

REPERTOIRE

Reviewed by CopyMark Law Group

Reg. 6303018Status 700Renewal
Filing date
Status date
Registration date
Mar 23, 2021
Examiner
YOUNG, THOMAS PAUL
Law office
PUBLICATION AND ISSUE SECTION

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with REPERTOIRE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $299*

Plus Government fees of $325

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

CHRISTINA M. LICURSI

CHRISTINA M. LICURSI WOLF, GREENFIELD & SACKS, P.C.600 ATLANTIC AVENUEBOSTON, MA 02210United States

Goods and services

ClassDescriptionStatusFirst use
005therapeutic products for medical purposes in the nature of biological preparations, biological tissue cultures and cell-based therapeutics in the nature of genetically modified cells used to modulate an immune response; pharmaceutical preparations used to modulate an immune response; pharmaceuticals and medical preparations for immunotherapy, cell therapy, immune cell therapy, and T-cell therapy for use in the prevention and treatment of cancer, tumors, and diseases and disorders of the immune system; pharmaceuticals and medical preparations for use in the prevention and treatment of cancer, tumors, and diseases and disorders of the immune system; pharmaceuticals and medical preparations in the nature of biotherapeutics, immunotherapeutics, immunomodulators, immunostimulants, immunogenics, antibodies, cell therapeutics, cells, immune cells, and T-cells for use in the prevention and treatment of cancer, tumors, and diseases and disorders of the immune systemACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 23, 2026REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 7, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 7, 2025CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 7, 2025COARTEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 23, 2021R.SRREGISTERED-SUPPLEMENTAL REGISTERYour mark is registered on the Supplemental Register, which is available for marks that are not yet distinctive enough for the Principal Register but can still identify a source. Protection is more limited than Principal Register registration but can later support a Principal Register application.
Feb 12, 2021PREVLAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 12, 2021AAUANOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
Feb 11, 2021ALIEASSIGNED TO LIE
Feb 11, 2021EXPTEXPARTE APPEAL TERMINATED
Feb 11, 2021CNTAAPPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
Feb 11, 2021XAECEXAMINER'S AMENDMENT ENTERED
Feb 11, 2021GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 11, 2021GNEAEXAMINERS AMENDMENT E-MAILED
Feb 11, 2021CNEAEXAMINERS AMENDMENT -WRITTEN
Feb 11, 2021IUAAUSE AMENDMENT ACCEPTED
Feb 4, 2021AUPCAMENDMENT TO USE PROCESSING COMPLETE
Feb 4, 2021IUAFUSE AMENDMENT FILED
Feb 3, 2021ERFRTEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 3, 2021EAAUTEAS AMENDMENT OF USE RECEIVED
Feb 3, 2021EXPIEX PARTE APPEAL-INSTITUTED
Feb 3, 2021JURTJURISDICTION RESTORED TO EXAMINING ATTORNEY
Feb 3, 2021EXAFEXPARTE APPEAL RECEIVED AT TTAB
Aug 3, 2020GNFNNOTIFICATION OF FINAL REFUSAL EMAILED
Aug 3, 2020GNFRFINAL REFUSAL E-MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Aug 3, 2020CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jul 15, 2020TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Jul 14, 2020CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 14, 2020TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 21, 2020GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 21, 2020GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 21, 2020CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 15, 2020DOCKASSIGNED TO EXAMINER
Apr 8, 2020ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jan 30, 2020NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Frequently asked questions

Related guidance